With its FDA approval this week, Vivitrol becomes the first non-addictive, non-narcotic, once-monthly treatment for opioid dependence, serving a potential market of 1.3 million addicts in the U.S. (BioWorld Today)

Upon receipt of a complete response letter from the FDA, Human Genome Sciences Inc. and Novartis AG have decided not to pursue Zalbin (albinterferon alfa-2b) in hepatitis C. (BioWorld Today)